{"entity":{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab and Polatuzumab vedotin in hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT03533283 by Hoffmann-La Roche, with 211 participants enrolled, started 2018-05-08 and due to reach its primary completion in 2026-10-16. Interventions recorded: Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab, Polatuzumab Vedotin and 89Zr-Df-IAB22M2C.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03533283","url":"https://clinicaltrials.gov/study/NCT03533283"}],"tags":["pipeline","ctgov-ingest"],"related":["zr-89"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03533283","phase":"1/2","setting":"An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","enrolled":211,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03533283/","neighbours":{"isotope":[{"id":"zr-89","kind":"isotope","name":"Zirconium-89","route":"/isotopes/zr-89/"}]}}